Trump’s watered-down Medicare drug pricing rule saves 96% less than initial proposal
The Trump administration finalized the GLOBE rule to lower Medicare Part B drug prices using a most-favored nation pricing model. The final rule is significantly more limited than the initial proposal, applying to only four companies. Medicare actuaries estimate the projected savings dropped from nearly $12 billion in the original proposal to $440 million, representing a 96% reduction in expected cost savings.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The Trump administration finalized a Medicare drug pricing rule known as the GLOBE rule.
- ✓ The final rule applies to only four companies.
- ✓ Medicare actuaries estimate projected savings fell from nearly $12 billion in the proposed rule to $440 million.
- ✓ The finalized rule delivers 96% less savings than the initial proposal.
What changed
CMS finalized the GLOBE rule, confirming a drop in projected savings from $11.9 billion to $440 million.
Live updates
-
Trump Administration Finalizes Medicare Drug Pricing Rule With Reduced Savings
The Trump administration finalized the GLOBE rule to lower Medicare Part B drug prices using a most-favored nation pricing model. The final rule is significantly more limited than the initial proposal, applying to only four companies. Medicare actuaries estimate the projected savings dropped from nearly $12 billion in the original proposal to $440 million, representing a 96% reduction in expected cost savings.
Why it matters
The rule aims to align US Medicare payments for certain drugs with lower prices paid in other developed nations. This effort targets high-cost prescriptions within the Part B program. The sharp decline in projected savings indicates a substantial narrowing of the policy's scope.
What is confirmed
- The Trump administration finalized a Medicare drug pricing rule known as the GLOBE rule.
- The final rule applies to only four companies.
- Medicare actuaries estimate projected savings fell from nearly $12 billion in the proposed rule to $440 million.
- The finalized rule delivers 96% less savings than the initial proposal.
- The model aims to bring most-favored nation pricing to Medicare Part B.
What to watch next
- Legal challenges from the four affected pharmaceutical companies
- Implementation timelines for the most-favored nation pricing model
confidence 100%Sources used for this update (9)
- WSJ — Trump Administration Finalizes Plan to Lower Drug Prices in Medicare
- STAT — Trump’s watered-down Medicare drug pricing rule saves 96% less than initial proposal
- Yahoo — What Medicaid’s New Payment Model Means For Your Prescriptions
- Fierce Healthcare — CMS finalizes model that aims to bring most-favored nation pricing to Part B
- Endpoints News — CMS finalizes GLOBE rule as projected Medicare savings fall from $11.9B to $440M
- www.statnews.com — Trump’s watered down drug pricing rule saves 96% less than ...
- catalystalert.io — Trump’s watered down drug pricing rule saves 96% less than ...
- www.statnews.com — Pharmalittle: Medicare drug-price rule saves far less than ...
- www.worldpingnews.com — Swiss glaciers suffer 'disastrous' year of ice loss ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community